Pages
- Isoprotrace
- FAPI Study Request
- Welcome to our FAPI site
- FAPI Articles
- Lu177 Treatments
- Privacy Policy
- Theranostics
- Radiopharmacy
- Products
- Tb161
- PET Products
- SPECT Products
- Services
- Cold Kits
- Radiopharmaceuticals Companys
- Partnerships & Distribution
- CMO
- Regulation and Quality
- Home
- Contact us
- IsoBlog
- Theranostics + Targeted Therapy
- LuPARP
- Careers
- Product Safety
- Testimonials
- Investors
- Our values
- Company profile
- Our Team
- News
- Sample request
- Lu177
News & Info
- Hanukkah 2019 – Family day at Isotopia
- Isoprotrace® received marketing authorization in the Netherlands
- QC כימאי/ת אנליטית למעבדת
- Isotopia USA partners with E Solutions and Comfort Systems
- רפרנט/ית הבטחת איכות
- Nuclear Medicine role in Neuroendocrine Tumors
- מתאם/ת ייצוא ושירות לקוחות
- מנהל/ת תפעול
- נהג חומ”ס
- טכנאי/ת ייצור לוטיציום
- עובד ייצור
- Terbium 161 for Targeted Radionuclide Therapy in Oncology
- Terbium-161 Radionuclide Therapy in Prostate Cancer
- Radiopharmacy and Radiobiology Aspects for 161-Terbium
- The Future of Theranostics in Prostate Cancer- PSMA RLT and Combination Therapy
- Todd Hockemeyer, CEO- Isotopia USA
- Isotopia is expanding its global footprint after filling a DMF in the US FDA and MF in Canada
- Is there a future for PSMA theranostics in Osteosarcoma?
- THE POTENTIAL ROLE OF PSMA THERANOSTICS IN CANCER OF THE ORAL CAVITY
- Successful implementation of a GMP-compliant eQMS solution
- PSMA theranostics in tumors other than prostate cancer
- Pilochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements
- Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
- Advancing clinical journey with our partners
- Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers
- 6th Theranostics World Congress- June 24-26, 2022- Wiesbaden, Germany.
- SNMMI 2022 annual meeting, 11-14, in Vancouver, Canada.
- We are looking for a VP of sales in Europe
- Nuclear imaging in Parkinson’s disease- The past, the present, and the future.
- Overcoming Lutetium-177 Production and Supply Challenges
- National Comprehensive Cancer Network® (NCCN) Guidelines® Version 03/2022
- Isotopia Molecular Imaging and Sinotau Pharmaceuticals Sign a Clinical Supply Agreement for 177Lu n.c.a
- Isotopia and the Peter MacCallum Cancer Center announce Terbium-161 clinical study collaboration
- Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a
- Isotopia Molecular Imaging and FutureChem sign a clinical supply agreement for 177Lu n.c.a
- HERMES MEDICAL SOLUTIONS & ISOTOPIA MOLECULAR IMAGING ANNOUNCE A NEW COLLABORATION FOCUSED ON DOSIMETRY
- POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement
- Getting to know Isotopia’s supply chain
- Elgan Pharma and Isotopia Molecular Imaging Signed on a Strategic agreement for Phase III and commercial Contract Manufacturing Services
- Israeli researchers developing radioactive marker to detect small, aggressive cancerous tumors
- Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics
- Isotopia and M.T.T.I signed for the supply of Lu-177 n.c.a
- Breaking news !
- ARTMS and Isotopia Molecular Imaging Announce successful Multi-Curie Labeling of PSMA-11
- Isotopia begins clinical supply collaboration with Y-mAbs Therapeutics,Inc
- Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177
- Isotopia Molecular Imaging files Drug Master File (DMF) with the U.S. Food and FDA for Lu177 n.c.a
- Vision study – Research on Prostate Cancer
- proPSMA study
- COVID-19 measures – Isotopia Molecular Imaging
- Isotopia’s announcement: GMP certificate was given for Lu177 chloride
- Isotopia Molecular Imaging and Eckert & Ziegler to start Partnership for Prostate Cancer Imaging
- 18F-DOPA use in Parkinsonism
- Lutetium 177 production (Lu177 production)
- PERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY
- Prostate cancer
- CNIC establishes global partnership with Isotopia Molecular Imaging Ltd. to put patients first
- Tech transfer for isoPROtrace-11 completed
- EANM 2019 Barcelona
- FDA inspection
- Lu-177 n.c.a status update
- The first Radio-pharmacy GPP certified
- Israeli Nuclear Medicine Conference INM
- Isotopia completes the acquisition of the pharmaceutical aseptic plant located in soreq
- Isotopia participated in the PDA convention
- 15th Annual Update Conference on Clinical Neurology & Neurophysiology
- F-DOPA reimbursed for Israeli patients
- EANM 2018 Germany
- Isotopia starts Lu-177 c.a
